<--- Back to Details
First PageDocument Content
Pharmacology / Levofloxacin / Ofloxacin / New Drug Application / Food and Drug Administration / Structured Product Labeling / Adverse effect / Piperazines / Medicine / Chemistry
Date: 2009-04-02 10:58:02
Pharmacology
Levofloxacin
Ofloxacin
New Drug Application
Food and Drug Administration
Structured Product Labeling
Adverse effect
Piperazines
Medicine
Chemistry

Add to Reading List

Source URL: www.accessdata.fda.gov

Download Document from Source Website

File Size: 21,32 KB

Share Document on Facebook

Similar Documents

Findings that shed new light on the possible pathogenesis of a disease or an adverse effect Chronic carbon monoxide poisoning resulting in bilateral cataracts and a cystic globus pallidus lesion Shivani Kasbekar,1 Jose A

DocID: 1uw60 - View Document

Press contact: Eric Young, , (orcell) Experiment suggests that pop-up ads can have an adverse effect on consumers’ perceptions of the content. CHICAGO, April 18, 2017

DocID: 1tKSS - View Document

Medicine / Clinical medicine / Chemistry / Lactones / Enzyme inhibitors / Formamides / Aldehydes / Hoffmann-La Roche / Orlistat / Anti-obesity medication / Adverse effect / Sibutramine

orlistat and pcoc orlistat 60 mg studies persistence analysis sibutramine orlistat, clinical studies orlistat, orlistat and gall stones does orlistat work, health problems and orlistat orlistat and appetite. orlistat pre

DocID: 1rrCO - View Document

Pharmaceutical sciences / Pharmacology / Pharmaceuticals policy / Health care / Pharmacy / Drugs / Clinical pharmacology / Pharmaceutical industry / Formulary / Prescription drug / Pharmaceutical drug / Adverse effect

NON-INSURED HEALTH BENEFITS First Nations and Inuit Health Branch DRUG BENEFIT LIST 2016

DocID: 1rp6w - View Document

Medicine / Neurochemistry / Clinical medicine / RTT / General anesthetics / Dosage forms / Calcium channel blockers / Sodium channel blockers / Ketamine / Adverse effect / Intravenous therapy / FOLFOX

Package leaflet: Information for the user Elaprase 2 mg/ml concentrate for solution for infusion Idursulfase ▼This medicine is subject to additional monitoring. This will allow quick identification of new safety inform

DocID: 1reFq - View Document